Therapeutic targets in triple negative breast cancer - where are we now?

Recent Patents on Anti-Cancer Drug Discovery

Volumn 6, Issue 2, 2011, Pages 196-209

  Teng, Yvonne H F ^a   Thike, Aye Aye ^a   Wong, Nan Soon ^b   Tan, Puay Hoon ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Basal like; BRCA 1; Targets; Treatment; Triple negative

Indexed keywords

4 IODO 3 NITROBENZAMIDE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRCA1 PROTEIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EVEROLIMUS; GEMCITABINE; IMATINIB; IRINOTECAN; OLAPARIB; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; STEM CELL FACTOR RECEPTOR; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

AGE; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER REGRESSION; CLINICAL FEATURE; DOSAGE SCHEDULE COMPARISON; DRUG RESPONSE; DRUG TARGETING; HISTOPATHOLOGY; HUMAN; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RACE DIFFERENCE; TRIPLE NEGATIVE BREAST CANCER;

ANTINEOPLASTIC AGENTS; BRCA1 PROTEIN; BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; PATENTS AS TOPIC; PROGNOSIS;

EID: 79954504770     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489211795328521     Document Type: Article

References (151)

1. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996; 13: 63-72.
2. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
3. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-74.
4. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-23.
5. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003; 100: 10393-8.
6. Benz, C., Esserman, L., Waldman, F., Yau, C. Multi-gene classifiers and prognostic indicators for cancers. WO2009114534 (2009).
7. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007; 9: R65.
8. Reis-Filho JS, Tutt AN. Triple negative tumours: A critical review. Histopathology 2008; 52: 108-18.
9. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, et al. Race and triple negative threats to breast cancer survival: A population-based study in Atlanta, GA. Breast Cancer Res Treat 2009; 113: 357-70.
10. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: A single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 2007; 110: 876-84.
11. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative nvasive breast cancer, the so-called triple-negative phenotype: Apopulation-based study from the California Cancer Registry. Cancer 2007; 109: 1721-8.
12. Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, et al. Population differences in breast cancer: Survey in indigenous african women reveals over-representation of triple-negative breast cancer. J Clin Oncol 2009; 27: 4515-21.
13. Rhee J, Han SW, Oh DY, Kim JH, Im SA, Han W, et al. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer 2008; 8: 307.
14. Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, Miyamoto K, et al. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer 2010; 17(2): 118-24.
15. Toyama T, Yamashita H, Kondo N, Okuda K, Takahashi S, Sasaki H, et al. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers. BMC Cancer 2008; 8: 309.
16. Kurebayashi J, Moriya T, Ishida T, Hirakawa H, Kurosumi M, Akiyama F, et al. The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast 2007; 16 (Suppl 2): S72-S7.
17. Yin WJ, Lu JS, Di GH, Lin YP, Zhou LH, Liu GY, et al. Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res Treat 2009; 115: 325-33.
18. Thike AA, Poh YC, Jara-Lazaro AR, Tan B, Tan P, Tan PH. Triple negative breast cancer: Clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol 2010; 23: 123-33.
19. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-34.
20. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-502.
21. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19: 264-71.
22. Fulford LG, Easton DF, Reis-Filho JS, Sofronis A, Gillett CE, Lakhani SR, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 2006; 49: 22-34.
23. Williams DJ, Cohen C, To TV, Page AJ, Lawson D, Sussman ZM, et al. Triple-negative breast carcinoma in women from Vietnam and the United States: Characterization of differential marker expression by tissue microarray. Hum Pathol 2009; 40: 1176-81.
24. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006; 24: 5652-7.
25. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109: 25-32.
26. Tischkowitz M, Brunet JS, Bégin LR, Huntsman DG, Cheang MC, Akslen LA, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 2007; 7: 134.
27. Ko ES, Lee BH, Kim HA, Noh WC, Kim MS, Lee SA. Triplenegative breast cancer: Correlation between imaging and pathological findings. Eur Radiol 2010; 20(5): 1111-7.
28. Kojima Y, Tsunoda H. Mammography and ultrasound features of triple-negative breast cancer. Breast Cancer 2010. [Epub ahead of print].
29. Yang WT, Dryden M, Broglio K, Gilcrease M, Dawood S, Dempsey PJ, et al. Mammographic features of triple receptornegative primary breast cancers in young premenopausal women. Breast Cancer Res Treat 2008; 111(3): 405-10.
30. Ma H, Luo J, Press MF, Wang Y, Bernstein L, Ursin G. Is there a difference in the association between percent mammographic density and subtypes of breast cancer? Luminal A and triplenegative breast cancer. Cancer Epidemiol Biomarkers Prev 2009; 18(2): 479-85.
31. Banerjee S, Reis-Filho JS, Ashley S, Steele D, Ashworth A, Lakhani SR, et al. Basal-like breast carcinomas: Clinical outcome and response to chemotherapy. J Clin Pathol 2006; 59: 729-35.
32. Liu ZB, Liu GY, Yang WT, Di GH, Lu JS, Shen KW, et al. Triplenegative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients. Oncol Rep 2008; 20(4): 987-94.
33. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-85.
34. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-74.
35. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, et al. Triple-negative breast cancer: Distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009; 15: 2302-10.
36. Tan DS, Marchió C, Jones RL, Savage K, Smith IE, Dowsett M, et al. Triple negative breast cancer: Molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008; 111: 27-44.
37. Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F. p63, cytokeratin 5, and P-cadherin: Three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 2005; 447: 688-94.
38. Li H, Cherukuri P, Li N, Cowling V, Spinella M, Cole M, et al. Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. Cancer Res 2007; 67: 501-10.
39. Rodríguez-Pinilla SM, Sarrió D, Honrado E, Moreno-Bueno G, Hardisson D, Calero F, et al. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J Clin Pathol 2007; 60: 1006-12.
40. Rakha EA, El-Sayed ME, Green AR, Paish EC, Lee AH, Ellis IO. Breast carcinoma with basal differentiation: A proposal for pathology definition based on basal cytokeratin expression. Histopathology 2007; 50: 434-8.
41. Yamamoto Y, Ibusuki M, Nakano M, Kawasoe T, Hiki R, Iwase H. Clinical significance of basal-like subtype in triple-negative breast cancer. Breast Cancer 2009; 16: 260-7.
42. Liu ZB, Wu J, Ping B, Feng LQ, Di GH, Lu JS, et al. Basal cytokeratin expression in relation to immunohistochemical and clinical characterization in breast cancer patients with triple negative phenotype. Tumor 2009; 95: 53-62.
43. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14: 1368-76.
44. Sasa M, Bando Y, Takahashi M, Hirose T, Nagao T. Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer. J Surg Oncol 2008; 97: 30-4.
45. Foulkes WD, Stefansson IM, Chappuis PO, Bégin LR, Goffin JR, Wong N, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003; 95: 1482-5.
46. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005; 11: 5175-80.
47. Honrado E, Benitez J, Palacios J. Histopathology of BRCA1-and BRCA2-associated breast cancer. Crit Rev Oncol Hematol 2006; 59: 27-39.
48. +) phenotype of BRCA1-related breast cancer. Cancer Res 2004; 64: 830-5.
49. Lakhani S, Reis-Filho JS, Fulford LG, Vijver MV, Penault-Llorca F, McGuffog L, et al. Basal markers and estogen receptor status are powerful predictors of germline BRCA1 mutations. AACR Meeting Abstracts 2004; 2004: 1292.
50. Brekelmans CT, Seynaeve C, Menke-Pluymers M, Brüggenwirth HT, Tilanus-Linthorst MM, Bartels CC, et al. Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol 2006; 17(3): 391-400.
51. Kriege M, Seynaeve C, Meijers-Heijboer H, Collee JM, Menke-Pluymers MB, Bartels CC, et al. Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1-and BRCA2-associated compared to sporadic breast cancer patients. Breast Cancer Res Treat 2008; 111(2): 303-11.
52. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, et al. Gene expression profiles in hereditary breast cancer. N Engl J Med 2001; 344: 539-48.
53. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, et al. BRCA1 mutations in primary breast and ovarian carcinoma. Science 1994; 266: 120-2.
54. Turner NC, Reis-filho JS, Russell AM, Springall RJ, Ryder K, Steele D, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007; 14: 2126-32.
55. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, et al. High-throughput protein expression analysis using tissue microarray technology of a large well characterized series identifies biologically distince classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005; 116: 340-52.
56. Matros E, Wang ZC, Lodeiro G, Miron A, Iglehart JD, Richardson AL. BRCA1 promoter methylation in sporadic breast tumors:Relationship to gene expression profiles. Breast Cancer Res Treat 2005; 91: 179-86.
57. Esteller M, Silva M, Domingues G, Bonilla F, Matias-Guiu X, Lerma E, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 92: 564-9.
58. Osin P, Lu YJ, Stone J, Crook T, Houlston RS, Gasco M, et al. Distince genetic and epigenetic changes in medullary breast cancer. Int J Surg Pathol 2003; 11: 153-8.
59. Huober J, von Minckwitz G, Denkert C, Kleine-Tebbe A, Weiss E, Zahm D, et al. Neoadjuvant chemotherapy in operable breast cancer with docetaxel, doxorubicin, and cyclophosphamide (TAC) or TAC followed by vinorelbine and capecitabine (NX): Final results and analysis of markers predicting response to treatment. J Clin Oncol (Meeting Abstracts) 2009; 27: 524.
60. Rugo HS, Thomas ES, Lee RK, Fein LE, Peck R, Verrill M. Combination therapy with the novel epothilone B analog, ixabepilone, plus capecitabine has efficacy in ER/PR/HER2-negative breast cancer resistant to anthracyclines and taxanes. Proceedings of the San Antonio Breast Cancer Symposium. San Antonio, Texas, USA, December 13-16, 2007.
61. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-34.
62. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-81.
63. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000; 275: 23899-903.
64. Yun J, Zhong Q, Kwak JY, Lee WH. Hypersensitivity of Brca1-deficient MEF to the DNA interstrand crosslinking agent mitomycin C is associated with defect in homologous recombination repair and aberrant S-phase arrest. Oncogene 2005; 24: 4009-16.
65. Moynahan ME, Cui TY, Jasin M. Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a BRCA1 mutation. Cancer Res 2001; 61: 4842-50.
66. Sgagias MK, Wagner KU, Hamik B, Stoeger S, Spieker R, Huber LJ, et al. BRCA1-deficient murine mammary epithelial cells have increased sensitivity to CDDP and MMS. Cell Cycle 2004; 3: 1451-6.
67. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003; 97: 2187-95.
68. Garber JE, Richardson A, Harris LN, Miron A, Silver D, Golshan M, et al. Neo-Adjuvant Cisplatin (CDDP) in triple-negative breast cancer (BC). Proceedings of the San Antonio Breast Cancer Symposium. San Antonio, Texas, USA, December 14-17, 2006.
69. Sikov WM, Dizon DS, Strenger R, Legare RD, Theall KP, Graves TA, et al. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: ABrown University Oncology Group Study. J Clin Oncol 2009; 27: 4693-700.
70. Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G, et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 2008; 19: 1847-52.
71. Leone JP, Guardiola V, Venkatraman A, Pegram MD, Welsh C, Silva O, et al. Neoadjuvant platinum-based chemotherapy (CT) for triple-negative locally advanced breast cancer (LABC): Retrospective analysis of 125 patients. J Clin Oncol (Meeting Abstracts) 2009; 27: 625.
72. National Institutes of Health. Available at: www. clinicaltrials.gov. (Accessed on: Jan 10, 2010)
73. Uhm JE, Park YH, Yi SY, Cho EY, Choi YL, Lee SJ, et al. Treatment outcomes and clinicopathologic characteristics of triplenegative breast cancer patients who received platinum-containing chemotherapy. Int J Cancer 2009; 124: 1457-62.
74. Chia JW, Ang P, See H, Wong Z, Soh L, Yap Y, et al. Triplenegative metastatic/recurrent breast cancer: Treatment with paclitaxel/carboplatin combination chemotherapy. J Clin Oncol (Meeting Abstracts) 2007; 25: 1086.
75. Nogi H, Kobayashi T, Suzuki M, Tabei I, Kawase K, Toriumi Y, et al. EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer. Oncol Rep 2009; 21: 413-7.
76. Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 2007; 117: 1370-80.
77. Pinilla SM, Honrado E, Hardisson D, Benítez J, Palacios J. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat 2006; 99: 85-90.
78. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Superior efficacy of albumin-bound paclitaxel, ABI-007, compared with polyethylated castor oil-based paclitaxel in women with metastatic breast cancer: Results of a phase III trial. J Clin Oncol 2005; 23: 7794-803.
79. Desai N, Yao Z, Trieu V, Soon-Shiong P, Dykes D, Noker P. Evidence of greater antitumor activity of cremophor-free nanoparticle albumin-bound (nab) paclitaxel (Abraxane) compared to taxol: Role of a novel albumin transporter mechanism. Proceedings of the San Antonio Breast Cancer Symposium. San Antonio, Texas, USA, December 3-6, 2003.
80. Jirstrom, K., Eberhard, J. Prediction of response to platinum-based therapy. WO2010092190 (2010).
81. Ellisen, L.W., Leong, C.O. Methods to determine the responsiveness to cisplatin treatment. US20100035257 (2010)
82. Viale G, Rotmensz N, Maisonneuve P, Bottiglieri L, Montagna E, Luini A, et al. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: Prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 2009; 116: 317-28.
83. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: Acomparison with hormone receptor and Her2/neuoverexpressing phenotypes. Hum Pathol 2006; 37: 1217-26.
84. Lerma E, Peiro G, Ramón T, Fernandez S, Martinez D, Pons C, et al. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). Mod Pathol 2007; 20: 1200-7.
85. Reis-Filho J, Pinheiro C, Lambros M, Milanezi F, Carvalho S, Savage K, et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol 2006; 209: 445-53.
86. Reis-Filho JS, Milanezi F, Carvalho S, Simpson PT, Steele D, Savage K, et al. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: Immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res 2005; 7: R1028-R35.
87. Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, et al. EGFR gene amplification in breast cancer: Correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 2005; 18: 1027-33.
88. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
89. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
90. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23: 6829-37.
91. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer: Molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-44.
92. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti EGFR treatment in colorectal cancer: A cohort study. Lancet Oncol 2005; 6: 279-86.
93. Kancha RK, von Bubnoff N, Peschel C, Duyster J. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Clin Cancer Res 2009; 15: 460-7.
94. Brower, S.L., Rice, S.D., Buechel, H.M., Hancher, L.M. Methods for predicting a patient's response to EGFR inhibitors. US20090286276 (2009).
95. Powell, W.C., Kivi, L.W., Roche, P.C., Gooch, G., Gaire, F. Antibodies specific for the C-terminal regulatory domain of EGFR and their use. US20100285025 (2010).
96. Corkery B, Crown J, Clynes M, O'Donovan N. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol 2009; 20: 862-7.
97. Carey LA, Mayer E, Marcom PK, Rugo H, Liu M, Ma C, et al. TBCRC 001: EGFR inhibition with cetuximab in metastatic triple negative (basal-like) breast cancer. Proceedings of the San Antonio Breast Cancer Symposium. San Antonio, Texas, USA, Dec 13-16, 2007.
98. O'Shaughnessy J, Weckstein DJ, Vukelja SJ, McIntyre K, Krekow L, Holmes FA, et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Proceedings of the San Antonio Breast Cancer Symposium. San Antonio, Texas, USA, Dec 13-16, 2007.
99. Simon R, Panussis S, Maurer R, Spichtin H, Glatz K, Tapia C, et al. KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations. Clin Cancer Res 2004; 10: 178-83.
100. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-80.
101. Heinrich MC, Corless CL, Demetri GD, Blanke CD, Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-9.
102. Heinrich MC, Corless CL, Duensing A, Blanke CD, von Mehren M, Joensuu H et al. PDGFR_ activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708-10.
103. Weigel MT, Meinhold-Heerlein I, Bauerschlag DO, Schem C, Bauer M, Jonat W, et al. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling. Cancer Lett 2009; 273: 70-9.
104. Modi S, Seidman AD, Dickler M, Moasser M, D'Andrea G, Moynahan ME, et al. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat 2005; 90: 157-63.
105. Chew HK, Barlow WE, Albain K, Lew D, Gown A, Hayes DF, et al. A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338. Clin Breast Cancer 2008; 8: 511-5.
106. Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee BN, Francis D, et al. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: Clinical activity and biological correlations. Ann Oncol 2008; 19: 1713-9.
107. Ng, G., Shen, W. Humanized c-Kit antibody. US20070253951 (2007).
108. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 665861.
109. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007; 105: 319-26.
110. Pichot CS, Hartig SM, Xia L, Arvanitis C, Monisvais D, Lee FY, et al. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer 2009; 101: 38-47.
111. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
112. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
113. Quinn, T.P. VEGF-activated Fas ligands. US20090214508 (2009).
114. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 2001; 7: 987-9.
115. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-76.
116. Miles DW, Chan A, Romieu G, Dirix L, Cortés J, Pivot X, et al. Final overall survival (OS) results from the randomised, doubleblind, placebo-controlled, phase III AVADO study of bevacizumab (BV) plus docetaxel (D) compared with placebo (PL) plus D for the first-line treatment of locally recurrent (LR) or metastatic breast cancer (mBC). Proceedings of the San Antonio Breast Cancer Symposium. San Antonio, Texas, USA, Dec 9-13, 2009.
117. Brufsky A, Bondarenko IN, Smirnov V, Hurvitz S, Perez E, Ponomarova O, et al. RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of her2-negative metastatic breast cancer. Proceedings of the San Antonio Breast Cancer Symposium. San Antonio, Texas, USA, Dec 9-13, 2009.
118. Robert NJ, Dieras V, Glaspy J, Brufsky A, Bondarenko I, Lipatov O, et al. RIBBON-1: Randomized, double-blind, placebocontrolled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol (Meeting Abstracts) 2009; 27: 1005.
119. Linderholm BK, Hellborg H, Johansson U, Elmberger G, Skoog L, Lehtiö J, et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 2009; 20: 1639-46.
120. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005; 5: 921-9.
121. Okkenhaug K, Vanhaesebroeck B. New responsibilities for the PI3K regulatory subunit p85_. Sci STKE 2001; 65: PE1.
122. Yu J, Zhang Y, McIlroy Y, Rordorf-Nikolic T, Orr GA, Backer JM. Regulation of the p85/p110 phosphatidylinositol 3'-kinase: Stabilization and inhibition of the p110 catalytic subunit by the p85 regulatory subunit. Mol Cell Biol 1998; 18: 1379-87.
123. Corvera S, Czech MP. Direct targets of phosphoinositide 3-kinase products in membrane traffic and signal transduction. Trends Cell Biol 1998; 8: 442-6.
124. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002; 8: 1153-60.
125. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization. Nat Med 2002; 8: 114552.
126. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cellintrinsic death machinery. Cell 1997; 91: 231-41.
127. Brunet A, Bonni A, Zigmond MJ, Masters S, Fu H, Gotoh Y, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96: 857-68.
128. Kops GJ, de Ruiter ND, de Vries-Smits AM, Powell DR, Bos JL, Burgering BM. Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature 1999; 398: 630-4.
129. Ali IU, Schriml LM, Dean M. Mutational spectra of PTEN/MMAC1 gene: A tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 1999; 91: 1922-32.
130. López-Knowles E, O'Toole SA, McNeil CM, Millar EK, Qiu MR, Crea P, et al. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 2010; 126: 1121-31.
131. Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M, et al. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal like breast cancer cells. Breast Cancer Res 2008; 10: R101.
132. Dourdin N, Schade B, Lesurf R, Hallett M, Munn RJ, Cardiff RD, et al. Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis. Cancer Res 2008; 68: 2122-31.
133. Saal LH, Gruvberger-Saal SK, Persson C, Lövgren K, Jumppanen M, Staaf J, et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 2008; 40: 102-7.
134. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8: 627-44.
135. Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 2009; 27: 4536-41.
136. Lee, J.H., Park, K.S., Choi, K.S. Novel agent that inhibits angiogenesis and metastasis targeting mtor signaling pathway. US20090264357 (2009).
137. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005; 11: 5175-80.
138. Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, et al. Estrogen receptor status in BRCA1-and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 2004; 10: 2029-34.
139. Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007; 26: 2126-32.
140. Darzynkiewicz Z, Traganos F, Wlodkowic D. Impaired DNA damage response-An Achilles' heel sensitizing cancer to chemotherapy and radiotherapy. Eur J Pharmacol 2009; 625: 143-50.
141. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004; 96: 1659-68.
142. Powell SN, Kachnie LA. Therapeutic exploitation of tumor cell defects in homologous recombination. Anticancer Agents Med Chem 2008; 8: 448-60.
143. Tassone P, Martino MT, Ventura M, Pietragalla A, Cucinotto I, Calimeri T, et al. Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. Cancer Biol Ther 2009; 8: 648-53.
144. Chalmers AJ. The potential role and application of PARP inhibitors in cancer treatment. Br Med Bull 2009; 89: 23-40.
145. Ashworth A. A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008; 26: 3785-90.
146. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 2008; 105: 17079-84.
147. Alli E, Sharma VB, Sunderesakumar P, Ford JM. Defective repair of oxidative DNA damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res 2009; 69: 3589-96.
148. O'Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triplenegative breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol (Meeting Abstracts) 2009; 27: 3.
149. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol (Meeting Abstracts) 2009; 27: CRA501.
150. Leyland-Jones, B., Abramovitz, M. Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer. US20100210738 (2010)
151. Weaver, D., Sprott, K.M., Wang, X. DNA repair proteins associated with triple negative breast cancers and methods of use thereof. US20090239229 (2009)